How has been the historical performance of Fredun Pharma?

Answer:The historical performance of Fredun Pharma shows a steady growth trajectory in various financial metrics.

Breakdown:
In the fiscal year ending March 2025, Fredun Pharma reported net sales of 456.27 crore, with total operating income matching this figure as there was no other operating income. The total expenditure, excluding depreciation, was 401.36 crore, leading to an operating profit (PBDIT) of 54.91 crore, which reflects an operating profit margin of 12.16%. After accounting for interest expenses of 22.38 crore and depreciation of 5.04 crore, the profit before tax stood at 27.49 crore, resulting in a profit after tax of 19.74 crore, which corresponds to a PAT margin of 4.37%. The earnings per share (EPS) was reported at 41.82, while the diluted EPS was slightly higher at 44.83. On the balance sheet side, total assets increased to 307.60 crore in March 2024, up from 257.28 crore in the previous year, with total liabilities also rising to 105.51 crore. The book value per share adjusted to 255.15, indicating a solid increase from the previous year. Cash flow analysis reveals a net cash outflow of 2.00 crore for March 2024, with cash and cash equivalents at the end of the period reported at 1.00 crore. Overall, Fredun Pharma demonstrates a positive growth trend in sales, profits, and asset management, despite facing some challenges in cash flow.